Cite
HARVARD Citation
Dillon, R. et al. (2021). How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). British journal of haematology. pp. 231-244. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dillon, R. et al. (2021). How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). British journal of haematology. pp. 231-244. [Online].